

11201810627U

Text of the abstract

Methods and compositions for constructing and producing recombinant adenovirus-based vector vaccines are provided. In particular, the adenovirus vector is replication defective and comprises a modified HPV16 E6 antigen, a modified HPV16 E7 antigen, or a combination of both. The vaccines may be used to generate high reactive anti-HPV and anti-tumor immune responses in subjects with pre-existing immunity to adenovirus.